Prolonged dual antiplatelet therapy for Chinese ACS patients undergoing emergency PCI with drug-eluting stents: Benefits and risks

被引:0
|
作者
Zhang, Yong [1 ]
Chu, Chao [1 ]
Zhong, Zhong [2 ]
Luo, Yong-bai [1 ]
Ning, Fei-Fei [1 ]
Guo, Ning [1 ]
机构
[1] Xi An Jiao Tong Univ, Affiliated Hosp 1, Dept Cardiovasc Med, Xian, Shaanxi, Peoples R China
[2] Weinan Cent Hosp, Dept Cardiovasc Med, Weinan, Shaanxi, Peoples R China
来源
关键词
dual antiplatelet therapy (DAPT); acute coronary syndrome (ACS); major adverse cardiovascular and cerebrovascular event (MACCE); composite bleeding event; emergency percutaneous coronary intervention (PCI); ACUTE MYOCARDIAL-INFARCTION; CLOPIDOGREL; IMPLANTATION; MANAGEMENT; DURATION; ESC;
D O I
10.3389/fcvm.2023.1080673
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
BackgroundIn patients with acute coronary syndrome (ACS), prolonged dual antiplatelet therapy (DAPT) may reduce ischemic events and increase the risks of bleeding events differently in different ethnic groups. However, whether prolonged DAPT in Chinese patients with ACS following emergency percutaneous coronary intervention (PCI) with drug-eluting stents (DES) will be beneficial or dangerous remains unclear. This study aimed to examine the potential benefits and risks of prolonged DAPT in Chinese patients with ACS who have undergone emergency PCI with DES. MethodsThis study included 2,249 patients with ACS who underwent emergency PCI. If DAPT was continued for 12 or 12-24 months, it was classified as the standard (n = 1,011) or prolonged (n = 1,238) DAPT group, respectively. The incidence of the following endpoint events was determined and compared between the two groups: composite bleeding event (BARC 1 or 2 types of bleeding and BARC 3 or 5 types of bleeding) and major adverse cardiovascular and cerebrovascular events (MACCEs) [ischemia-driven revascularization, non-fatal ischemia stroke, non-fatal myocardial infarction (MI), cardiac death, and all-cause death]. ResultsAfter a median period of 47 months of follow-up [47 (40, 54)], the rate of composite bleeding events was 13.2% (n = 163) in the prolonged DAPT group and 7.9% (n = 80) in the standard DAPT group [odds ratio (OR) 1.765, 95% confidence interval (CI) 1.332-2.338, p < 0.001]. The rate of MACCEs was 11.1% (n = 138) in the prolonged DAPT group and 13.2% (n = 133) in the standard DAPT group (OR 0.828, 95% CI 0.642-1.068, p = 0.146). The DAPT duration was further shown to be insignificantly correlated with MACCEs as per the multivariable Cox regression model (HR, 0.813; 95% CI, 0.638-1.036; p = 0.094). No statistically significant difference was observed between the two groups. However, the DAPT duration was a separate predictor of composite bleeding events according to the multivariable Cox regression model (HR 1.704, 95% CI 1.302-2.232, p < 0.001). Compared with the standard DAPT group, the prolonged DAPT group had substantially more BARC 3 or 5 types of bleeding events (3.0 vs. 0.9% in those with standard DAPT, OR 3.430, 95% CI 1.648-7.141, p < 0.001) and BARC 1 or 2 types of bleeding events (10.2 vs. 7.0% in those with standard DAPT, OR 1.500, 95% CI 1.107-2.032, p = 0.008). ConclusionThe prolonged DAPT group had a considerably greater incidence of composite bleeding events than the standard DAPT group. No statistically significant difference was observed in the incidence of MACCEs between the two groups.
引用
收藏
页数:14
相关论文
共 50 条
  • [1] Impact of prolonged dual antiplatelet therapy on patients after drug-eluting stents implantation
    何鹏程
    谭宁
    杨大浩
    陈纪言
    罗建方
    周颖玲
    [J]. South China Journal of Cardiology, 2012, 13 (01) : 1 - 7
  • [2] Dual Antiplatelet Therapy Duration in Patients With Drug-Eluting Stents
    Bondar, Maria
    Ilia, Mina
    Fletcher, Hollie
    [J]. US PHARMACIST, 2016, 41 (02) : HS2 - HS5
  • [3] Prolonged antiplatelet therapy after drug-eluting stents
    Curzen, Nick
    [J]. LANCET, 2015, 385 (9985): : 2332 - 2333
  • [4] Duration of Dual Antiplatelet Therapy after Drug-Eluting Stents
    Dohan, J. Lawrence
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2015, 372 (14): : 1371 - 1371
  • [5] Drug-eluting stents - Dual antiplatelet therapy for every survivor?
    Bavry, Anthony A.
    Bhatt, Deepak L.
    [J]. CIRCULATION, 2007, 116 (07) : 696 - 699
  • [6] Impact of Anemia and Dual Antiplatelet Therapy on Mortality in Patients Undergoing Percutaneous Coronary Intervention with Drug-Eluting Stents
    Wang, Huili
    Yang, Yuan
    Ma, Lufeng
    Wang, Xian
    Zhang, Jun
    Fu, Jinguo
    Zhang, Shouyan
    Zhang, Ling
    Hu, Dayi
    Ding, Rongjing
    [J]. SCIENTIFIC REPORTS, 2015, 5
  • [7] Are at Least 12 Months of Dual Antiplatelet Therapy Needed for All Patients With Drug-Eluting Stents? All Patients With Drug-Eluting Stents Need at Least 12 Months of Dual Antiplatelet Therapy Response
    Podrid, Philip J.
    [J]. CIRCULATION, 2015, 131 (22) : 2020 - 2020
  • [8] Impact of Anemia and Dual Antiplatelet Therapy on Mortality in Patients Undergoing Percutaneous Coronary Intervention with Drug-Eluting Stents
    Huili Wang
    Yuan Yang
    Lufeng Ma
    Xian Wang
    Jun Zhang
    Jinguo Fu
    Shouyan Zhang
    Ling Zhang
    Dayi Hu
    Rongjing Ding
    [J]. Scientific Reports, 5
  • [9] Duration of Dual Antiplatelet Therapy after Drug-Eluting Stents REPLY
    Mauri, Laura
    Yeh, Robert W.
    Kereiakes, Dean J.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2015, 372 (14): : 1373 - 1374
  • [10] Deciphering Dual Antiplatelet Therapy in the Era of Drug-Eluting Coronary Stents
    Bell, Brendan
    Walters, Darren
    Spaulding, Christian
    [J]. CURRENT DRUG TARGETS, 2009, 10 (06) : 519 - 529